Adverum Biotechnologies Total Revenue

The latest total revenue for ADVM is $-3.6M as of September 2025. That compares with $-2.6M in the prior-year period — down 38.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Adverum Biotechnologies's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADVM's total revenue moved from $-2.6M to $-3.6M — a 38.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adverum Biotechnologies's operating scale or balance-sheet position.

Against Healthcare companies, ADVM currently prints $-3.6M for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Adverum Biotechnologies's growth, margins, and balance sheet.

A total revenue figure of $-3.6M for ADVM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting ADVM's total revenue ($-3.6M), review year-over-year change from $-2.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.